Brief: Novocure Announces FDA Acceptance Of The Pma Application For Ttfields Therapy In Non-Small Cell Lung Cancer
Jan 18 (Reuters) - Novocure Ltd NVCR.O :
* NOVOCURE ANNOUNCES FDA ACCEPTANCE OF THE PMA APPLICATION
FOR
TTFIELDS THERAPY IN NON-SMALL CELL LUNG CANCER
* NOVOCURE LTD - PMA APPLICATION FOR LUNAR WAS SUBMITTED
WITH A
FILING DATE OF DECEMBER 15, 2023, AND IS NOW UNDER SUBSTANTIVE
REVIEW BY FDA
* NOVOCURE LTD - NOVOCURE EXPECTS TO RECEIVE A REGULATORY
DECISION
FROM FDA IN SECOND HALF 2024
Source text for Eikon: ID:nBw2Xw3R4a
Further company coverage: NVCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovoCure
See all newsOncology firm Novocure says cyberattack exposed US patient records
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture